Adam Hanina is co-founder and CEO of Ai Cure Technologies, an NIH-funded digital health company that has developed facial recognition software to confirm medication adherence on mobile devices. He is a passionate advocate for the use of healthcare software as a population health tool and has directed much of his previous work to this end. Mr. Hanina has focused on disruptive service delivery models, working to build sustainable and flexible platforms that can be easily adopted across multiple populations and disease states and which address the needs and concerns of diverse stakeholders.
Prior to Ai Cure, Mr. Hanina was responsible for developing Cerner Corporation’s European strategy and was a Visiting Fellow of eHealth at Imperial College in London, UK. Mr. Hanina has spoken extensively on the topic of healthcare innovation and has held numerous advisory board positions including for the Indian High Commission’s Healthcare, Pharmaceutical, & Biotech Committee, and for Deloitte Consulting’s Health Informatics Network for Europe (HINE).
Mr. Hanina has been responsible for much of the vision and strategy at Ai Cure Technologies and is the primary architect of the underlying technology in the majority of its global patent applications. Mr. Hanina has acted as a subject-matter expert on medication adherence technologies for the National Institutes of Health (NIH) and is currently a principal investigator for multiple NIH innovation grants. He holds an MBA from the Wharton School of Business.